arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Twist Bioscience Corp

TWST
$158.55 ▼ -5.97 (-3.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Twist Bioscience Corp faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.9B
Dividend Yield —
Revenue Growth 23.2% ↗
Op. Margin -30.6% ↗
ROIC -8.2% ↗
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 22.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$118.38M
↑ +23.2% —
Net Income Profit after all expenses
$-35.05M
↑ +20.4% —
Operating Margin Operating profit as % of sales
-30.6%
↑ +26.0% 7th
FCF / Share Free cash flow per share
$-0.14
↑ +66.4% —
Long-Term Debt Long-term obligations
$625.00K
↓ -71.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↑
29
Cash Quality ↑
64

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 37 quarters